Evidence map›Paper›PMID 30186543›Full record

ArticleOxidative medicine and cellular longevity2018

NRF2 Activation Inhibits Both TGF-

Yasutaka Mitamura, Mika Murai, Chikage Mitoma, Masutaka Furue

Open access · hybridAbstract read
In one paragraph

Article in Oxidative medicine and cellular longevity, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 49 citations in OpenAlex.

  1. Molecular Insights of Neuroprotective Effect ofInternational journal of molecular sciences · 2026
    Article
  2. Article
  3. Review
  4. From Pathways to Patients in Atopic Dermatitis: Advanced Systemic Therapies.International journal of molecular sciences · 2025
    Review
  5. Article
  6. Article
  7. Pericytes: The lung-forgotten cell type.Frontiers in physiology · 2023
    Review
  8. Journal of clinical medicine · 2022
    Review
  9. Type 2 Inflammation Contributes to Skin Barrier Dysfunction in Atopic Dermatitis.JID innovations : skin science from molecules to population health · 2022
    Review
  10. Article
  11. Review
  12. Article
  13. Inhibition ofFrontiers in cell and developmental biology · 2021
    Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Yasutaka Mitamura *Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.ORCID 0000-0001-6389-9285
Mika Murai *Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Chikage MitomaDepartment of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Masutaka FurueDepartment of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Kyushu University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Systemic fibrosing or sclerotic disorders are life-threatening, but only very limited treatment modalities are available for them. In recent years, periostin (POSTN), a major extracellular matrix component, was established by several studies as a novel key player in the progression of systemic fibrotic disease. In this research, we revealed the involvement of oxidative stress in the expression of POSTN induced by TGF-

Indexed as

AcroleinCell Adhesion MoleculesCells, CulturedDown-RegulationFibroblastsFibrosisHeme Oxygenase-1HumansInterleukin-13NF-E2-Related Factor 2Reactive Oxygen SpeciesRNA, MessengerTransforming Growth Factor beta1AcroleinCell Adhesion MoleculescinnamaldehydeHeme Oxygenase-1HMOX1 protein, humanIL13 protein, humanInterleukin-13NFE2L2 protein, humanNF-E2-Related Factor 2POSTN protein, humanReactive Oxygen SpeciesRNA, MessengerTransforming Growth Factor beta1

Identifiers

PMID30186543
PMCPMC6112270
OpenAlexW2885670976

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.